Compare Cognizant Technology Solutions Corp (CTSH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Sana Biotechnology Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.15 (market cap $27.03B), while Sana Biotechnology Inc trades at $2.81 (market cap $836.71M). The key difference: Cognizant Technology Solutions Corp is far larger — about 32.3× Sana Biotechnology Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Sana Biotechnology Inc for 23 Days on average.
| CTSH | SANA | |
|---|---|---|
Market Cap | $27.03B | $836.71M |
Volume | 9,883,888 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $86.70 | $5.92 |
52-Week Low | $38.73 | $2.68 |
Typical Hold Time | 57 Days | 23 Days |
Enterprise Value | $28.08B | $749.96M |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $59.43, up 4.14% on the day, with a bullish technical signal from moving averages and support at $56. The company reported revenue of $21.11B in 2025, with a net income margin of 10.26%, and has beaten earnings estimates in two of the last three quarters. Recent news highlights its AI-driven initiatives and recognition as a top employer, reinforcing its competitive positioning in IT services.
CTSH presents a value opportunity with a P/E of 12.88 below sector averages, supported by stable cash flow and a consensus price target of $64.25. Risks include competitive pressures in IT services and potential volatility around the upcoming Q3 earnings report. The stock's current valuation and analyst buy ratings suggest upside potential, though investors should monitor execution on AI integration.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
